title: Aphthous ulcers associated with bupropion in a female adolescent: a case verified by rechallenge.
abstract: Bupropion, a dual norepinephrine and dopamine reuptake inhibitor, has been approved by the United States Food and Drug Administration for the treatment of major depressive disorder. The most common treatment-emergent adverse events reported with bupropion were headache, dry mouth, nausea and agitation. The following is a case report intended to draw attention to a rarely reported adverse effect of bupropion. This article describes a female adolescent with depression who developed aphthous ulcers while on high-dose bupropion with positive rechallenge. This is the first case report indicating the incidence of aphthous ulcers associated with bupropion treatment.
authors.affiliation: Department of Psychiatry, Beitou Armed Forces Hospital, No.60, Xinmin Road, Beitou District, Taipei City 112, Taiwan, ROC.
authors.forename: Chien-Kuan
authors.initials: CK
authors.lastname: Chiang
authors.forename: Yuan-Hwa
authors.initials: YH
authors.lastname: Chou
authors.forename: Ying-Hseuh
authors.initials: YH
authors.lastname: Chen
authors.forename: Chien-Bai
authors.initials: CB
authors.lastname: Sha
authors.forename: Chih-Sung
authors.initials: CS
authors.lastname: Liang
mesh_terms: D000293:Adolescent; D018687:Antidepressive Agents, Second-Generation / Q000009:adverse effects* / Q000627:therapeutic use; D016642:Bupropion / Q000009:adverse effects* / Q000627:therapeutic use; D003863:Depression / Q000188:drug therapy; D005260:Female; D006801:Humans; D013281:Stomatitis, Aphthous / Q000139:chemically induced*; D013624:Taiwan; D014481:United States
chemical_list: D018687:Antidepressive Agents, Second-Generation; D016642:Bupropion